Enhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor Therapy

Launched by MAYO CLINIC · May 2, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how starting a specific hormone therapy called aromatase inhibitors affects the skin quality and self-esteem of women who have survived breast cancer. The goal is to understand if this treatment can help improve not only the appearance of their skin but also their overall quality of life. If you are a postmenopausal woman aged 18 or older with a confirmed diagnosis of certain types of breast cancer (stages 0 to III) that is hormone receptor-positive, you might be eligible to participate.

Participants in the study will need to agree to avoid any facial treatments, like facials or injections, during the trial. If you join, you can expect to undergo assessments that will help researchers learn more about any changes in your skin and self-esteem as you start the aromatase inhibitor therapy. This study is currently recruiting, so if you think you might qualify and are interested in improving your skin health and self-confidence after cancer treatment, this could be an opportunity to consider.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • \* Female ≥ 18 years
• • Postmenopausal women suitable to receive aromatase inhibitor as per physician's discretion
• • Histologically confirmed adenocarcinoma of the breast stage 0-III with estrogen receptor (ER) and/or progesterone receptor (PR) positive per American Society of Clinical Oncology (ASCO)/ College of American Pathologists (CAP) guideline and any human epidermal growth factor receptor 2 (HER2)
• • Patients must not have received any prior chemotherapy or endocrine therapy for their current breast cancer. Patients who received tamoxifen or raloxifene or another agent for prevention of breast cancer may be included
• • Patients willing to avoid any facial procedures including facials, neurotoxin injections, fillers, or lasers during study period
• • Willing and able to provide consent
• Exclusion Criteria:
• • \* Patients who have previously taken AIs
• • Patients using prescription tretinoin, neurotoxin injections, fillers, facial lasers, microneedling, or facials within 6 months of study consent